Literature DB >> 24698888

The Surviving Sepsis Campaign: past, present and future.

Christa A Schorr1, R Phillip Dellinger2.   

Abstract

The Surviving Sepsis Campaign (SSC) was created in 2002 and consists of severe sepsis management guidelines and a sepsis performance improvement program. The second revision of the guidelines, published in 2013, are sponsored by 30 international scientific organizations and contain changes in recommendations for fluids and vasopressor administration. The new 3- and 6-hour sepsis 'bundles' (sets of care elements) include a software program that can be downloaded free from the Surviving Sepsis Campaign website (www.survivingsepsis.org). The traditional intensive care unit and emergency department champion-driven sepsis performance improvement program continues internationally with the kick off of a new grant-funded hospital floor sepsis performance improvement initiative.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Surviving Sepsis Campaign; sepsis; sepsis bundles; sepsis performance improvement; septic shock; severe sepsis

Mesh:

Year:  2014        PMID: 24698888     DOI: 10.1016/j.molmed.2014.02.001

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  22 in total

1.  Discovery of functionally selective C5aR2 ligands: novel modulators of C5a signalling.

Authors:  Daniel E Croker; Peter N Monk; Reena Halai; Geraldine Kaeslin; Zoe Schofield; Mike Cl Wu; Richard J Clark; Mark At Blaskovich; Dimitrios Morikis; Christodoulos A Floudas; Matthew A Cooper; Trent M Woodruff
Journal:  Immunol Cell Biol       Date:  2016-04-25       Impact factor: 5.126

Review 2.  Are there new approaches for diagnosis, therapy guidance and outcome prediction of sepsis?

Authors:  Dubravka Kojic; Benedikt H Siegler; Florian Uhle; Christoph Lichtenstern; Peter P Nawroth; Markus A Weigand; Stefan Hofer; Thorsten Brenner
Journal:  World J Exp Med       Date:  2015-05-20

3.  Prevention of Nosocomial Infection in the Neurosciences Intensive Care Unit: Remember the Basics.

Authors:  Rob Boots
Journal:  Neurocrit Care       Date:  2016-10       Impact factor: 3.210

4.  The Knowledge of the Physicians about Sepsis Bundles is Suboptimal: A Multicenter Survey.

Authors:  Zeliha Kocak Tufan; Fatma Civelek Eser; Emre Vudali; Ayse Batirel; Bircan Kayaaslan; Aliye Tanrici Bastug; Deniz Eray; Vedat Turhan; Fazilet Duygu; Duran Tok; Serife Altun; Cemal Bulut; Mehmet A Tasyaran
Journal:  J Clin Diagn Res       Date:  2015-07-01

5.  From the Cover: Prolonged Exposure to Volatile Anesthetic Isoflurane Worsens the Outcome of Polymicrobial Abdominal Sepsis.

Authors:  Sophia Koutsogiannaki; Matthew M Schaefers; Toshiaki Okuno; Mai Ohba; Takehiko Yokomizo; Gregory P Priebe; James A DiNardo; Soriano G Sulpicio; Koichi Yuki
Journal:  Toxicol Sci       Date:  2017-04-01       Impact factor: 4.849

Review 6.  Sepsis-induced immune dysfunction: can immune therapies reduce mortality?

Authors:  Matthew J Delano; Peter A Ward
Journal:  J Clin Invest       Date:  2016-01-04       Impact factor: 14.808

Review 7.  The immune system's role in sepsis progression, resolution, and long-term outcome.

Authors:  Matthew J Delano; Peter A Ward
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

Review 8.  Immunotherapy: A promising approach to reverse sepsis-induced immunosuppression.

Authors:  Naeem K Patil; Julia K Bohannon; Edward R Sherwood
Journal:  Pharmacol Res       Date:  2016-07-25       Impact factor: 7.658

9.  Sensitivity Patterns of Bacterial Pathogens Isolated from Blood Cultures of Under-Five Children with Pneumonia and Clinical Sepsis.

Authors:  Sufia Islam; Ashiqur Rahman Akand; Tasnova Tasnim Nova; Christian Lehmann; Mohammod Jobayer Chisti
Journal:  Life (Basel)       Date:  2021-05-18

10.  Volatile anesthetics isoflurane and sevoflurane directly target and attenuate Toll-like receptor 4 system.

Authors:  Toshiaki Okuno; Sophia Koutsogiannaki; Lifei Hou; Weiming Bu; Umeharu Ohto; Roderic G Eckenhoff; Takehiko Yokomizo; Koichi Yuki
Journal:  FASEB J       Date:  2019-11-02       Impact factor: 5.834

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.